Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.54 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27660234 | 0.74 | MPO (0.61) | MPOLTB4RCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL7941513 | 0.73 | TLR7 (0.56) | MPOLTB4RNUDT1 | |
| SCHEMBL7947642 | 0.71 | MPO (0.47) | MPOCYP2D6CYP1A2CYP3A4SMN1; SMN2 | |
| SCHEMBL16943987 | 0.70 | MPO (0.53) | MPOLTB4RCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL27765525 | 0.70 | MPO (0.60) | MPOLTB4RCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL9443830 | 0.70 | MPO (0.60) | MPOLTB4RCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL8008235 | 0.70 | CDK1 (0.62) | MPOLTB4RCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL10698612 | 0.69 | MPO (0.47) | MPOLTB4RCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL27313299 | 0.69 | DCPS (0.55) | MPOLTB4RCYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL3416553 | 0.69 | HTR6 (0.57) | MPOLTB4RCYP2D6CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2279742-A2 | Combinations for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20090005358-A1 | Compositions and methods for treating medical conditions | LG CHEM, LTD. (KR) | 2009-01-01 | — | — | US | claimed |
| WO-2009002507-A1 | COMPOSITIONS AND METHODS FOR TREATING MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2008-12-31 | — | — | WO | claimed |
| US-20080025965-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels | COMBINATORX, INCORPORATED | 2008-01-31 | — | — | US | claimed |
| US-20080003213-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | COMBINATORX, INC. | 2008-01-03 | — | — | US | claimed |
| WO-2007146012-A1 | TREATMENT OF PERIODONTAL DISEASE ASSOCIATED WITH INCREASED C-REACTIVE PROTEIN LEVELS | COMBINATORX, INCORPORATED (US) | 2007-12-21 | — | — | WO | claimed |
| WO-2007139753-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH INCREASED C-REACTIVE PROTEIN, INTERLEUKIN-6, OR INTERFERON-GAMMA LEVELS | COMBINATORX, INCORPORATED (US) | 2007-12-06 | — | — | WO | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| EP-1448205-A4 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1448205-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2003-06-26 | — | — | US | claimed |
| WO-2003030823-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-04-17 | — | — | WO | claimed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110223621-A1 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-1448205-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2003-06-26 | — | — | US | disclosed |
| WO-2003030823-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005358-A1 | Compositions and methods for treating medical conditions | ITCH, TSLP, P2RX5 | MPO 310/4885LTB4R 35/4885CDC7 3617/4885 |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | MPO 14/4885LTB4R 25/4885CDC7 4398/4885 |
| US-20080025965-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels | TYMP, TTR, TPMT | MPO 193/4885LTB4R 142/4885CDC7 3072/4885 |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | IL5, TSLP, TPMT | MPO 45/4885LTB4R 33/4885CDC7 4181/4885 |
| US-20080003213-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | IFNG, IL6, IL36G | MPO 431/4885LTB4R 416/4885CDC7 3236/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | MPO 14/4885LTB4R 25/4885CDC7 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.